Diabetes, especially type 1 diabetes, may be a particularly important factor in the etiology of Fuchs endothelial corneal dystrophy (FECD) in findings from a case-control study of about 149.000 US ...

Design Therapeutics is set to present significant safety findings from its Phase 1 trial of DT-168, highlighting progress in their clinical development for treating Fuchs endothelial corneal dystrophy ...

Important insights into the mechanisms behind Fuchs Endothelial Corneal Dystrophy (FECD), a common cause of age-related visual loss, have been revealed in a new study led by UCL researchers. The study ...

SAN DIEGO--(BUSINESS WIRE)--Trefoil Therapeutics today announced it has begun a Phase 2 clinical trial of its engineered Fibroblast Growth Factor-1, TTHX1114, to evaluate its safety and efficacy as a ...

Please provide your email address to receive an email when new articles are posted on . At the virtual European Society of Cataract and Refractive Surgeons meeting, Martin Dirisamer, MD, PhD, speaks ...

Please provide your email address to receive an email when new articles are posted on . Aurion Biotech has won the Prix Galien Award for Best Startup in Biotech/Pharma, recognizing the company’s ...

In 1910, Professor Ernst Fuchs, an Austrian ophthalmologist, published an article describing 13 patients with Fuchs’ dystrophy, a condition in the cornea that subsequently bears his name. The patients ...

INDIANAPOLIS--(BUSINESS WIRE)--Price Vision Group announced today that it is the first site to initiate patient treatment in a clinical trial evaluating use of an experimental drug treatment in ...

This story is part of a series on the current progression in Regenerative Medicine. This piece is part of a series dedicated to the eye and improvements in restoring vision. In 1999, I defined ...

The correct diagnosis is iridocorneal endothelial (ICE) syndrome. ICE syndrome should be in the differential diagnosis for any young to middle-aged adult who presents with an acquired unilateral ...